text:
using App.Models.Images;
using App.Models.Materials;
using App.Models.Orders;
using System;
using System.Collections.Generic;
using System.ComponentModel.DataAnnotations;
using System.Web;
using System.Web.Mvc;

namespace App.Models.Orders
{
	public class EditOrderInputModel
	{
		public IList<Material> SurfaceMaterials { get; set; }

		public IList<Material> FazerMaterials { get; set; }

		public IList<Material> HandlesMaterials { get; set; }

		public ICollection<Image> SketchImages { get; set; }

		public ICollection<Image> DesignImages { get; set; }

		public ICollection<Image> ResultImages { get; set; }

		public List<HttpPostedFileBase> PostedSketches { get; set; }

		public List<HttpPostedFileBase> PostedDesigns { get; set; }

		public List<HttpPostedFileBase> PostedResults { get; set; }

		[Required(ErrorMessage = " * Задължително!")]
		[Display(Name = "Име на проекта:")]
		[StringLength(250, MinimumLength = 3, ErrorMessage = " *Невалидна дължина!")]
		public string Title { get; set; }

		[Required(ErrorMessage = " * Задължително!")]
		[Display(Name = "Slug:")]
		[StringLength(250, MinimumLength = 3, ErrorMessage = " *Невалидна дължина!")]
		public string Slug { get; set; }

		[Required(ErrorMessage = " * Задължително!")]
		[Display(Name = "Допълнителна информация:")]
		[StringLength(2500, MinimumLength = 3, ErrorMessage = " *Невалидна дължина!")]
		[DataType(DataType.MultilineText)]
		public string OrderText { get; set; }

		[Required(ErrorMessage = " * Задължително!")]
		[Range(1, int.MaxValue, ErrorMessage = " * Задължително!")]
		public int BaseMaterialId { get; set; }

		[Required(ErrorMessage = " * Задължително!")]
		[Range(1, int.MaxValue, ErrorMessage = " * Задължително!")]
		public int DoorsMaterialId { get; set; }

		[Required(ErrorMessage = " * Задължително!")]
		[Range(1, int.MaxValue, ErrorMessage = " * Задължително!")]
		public int FazerMaterialId { get; set; }

		//[Required(ErrorMessage = " * Задължително!")]
		//[Range(1, int.MaxValue, ErrorMessage = " * Задължително!")]
		public int HandlesMaterialId { get; set; }

		[Display(Name = "Монтаж:")]
		public bool Installation { get; set; }

		[Display(Name = "Публична (Готови продукти):")]
		public bool IsPublic { get; set; }

		[Display(Name = "Брой:")]
		public int Count { get; set; }

		[Display(Name = "Цена:")]
		public decimal Price { get; set; }

		[Display(Name = "Начин на плащане:")]
		public string PaymentType { get; set; }

		[Display(Name = "Статус:")]
		public OrderState State { get; set; }

		[Display(Name = "Дата на поръчката:")]
		public DateTime RequestDate { get; set; }

		public string ClientId { get; set; }

		public string ClientFullName { get; set; }

		[Display(Name = "Имена на клиента:")]
		public string AnonymousClientName { get; set; }

		[Display(Name = "Email на клиента:")]
		public string AnonymousClientEmail { get; set; }

		[Display(Name = "Телефон на клиента:")]
		public string AnonymousClientPhone { get; set; }

		public int OrderCategoryId { get; set; }

		[Required(ErrorMessage = "Задължително!")]
		[Display(Name = "Категория")]
		public int SelectedCategoryId { get; set; }
		public IEnumerable<SelectListItem> Categories { get; set; }
	}
}


text:
Cindy Lee Act of Tenderness
If you thought Women were weird and loud, just wait until you hear what Patrick Flegel is doing these days. While his former bandmates continue down the post-punk path as Preoccupations, Flegel has gone in a decidedly stranger direction under the alter ego Cindy Lee. Act of Tenderness was the project's debut album back in 2015, and following the extremely limited original pressing, it's now getting a well-deserved wider run.
Act of Tenderness is a curious mix of pop classicism and creepy experimentalism. On the freaky end of the spectrum, "Quit Doing Me Wrong" is a ramshackle anti-rock deconstruction full of detuned guitar and "Bonsai Garden" sounds, like a horror movie murder scene soaked in static. These moments of ugliness make the melodic tracks even sweeter: "Operation" is beautifully spooky electro-pop with haunting falsetto hooks, while "Wandering and Solitude" has a gorgeous guitar lick that sounds like it was beamed in from the early '60s. With repeat listens, these glimmers of pop beauty become increasingly apparent, and even the harshest moments are eerily inviting rather than alienating.
Three years on from this debut album's original release, Cindy Lee still feels like an obscure curio compared to the buzz-band acclaim that Women once enjoyed. Hopefully this reissue gives this oddly beautiful album the attention it deserves. (W.25TH)
More Cindy Lee
25 Canadian Albums You Might Have Missed in 2020
The past year has been filled with plenty of incredible new music, including Exclaim!'s 50 Best Albums of 2020, but even the most fastidious...
Women's 'Public Strain' Gets 10th Anniversary Reissue with Bonus 'Rarities' Compilation
Women's Public Strain was arguably one of the most influential Canadian releases of the 2010s — and undeniably one of the best. Now, the alb...
16 Must-Hear Canadian Albums from Winter 2020
Each day may feel like it lasts an eternity, but we're finally a quarter of the way through 2020. With the sun shining and the weather warmi...
Patrick Flegel Announces New Cindy Lee Album 'Cat O' Nine Tails'
Nearly a month removed from releasing What's Tonight to Eternity, former Women frontman Patrick Flegel has readied another new album as Cind...
Cindy Lee What's Tonight to Eternity
After Women disbanded a decade ago, the Calgary noise rock outfit's rhythm section decided to further explore their brawnier persuasions und...

redpajama_set_name: RedPajamaCommonCrawl


text:
Bama Basketball Breakdown: #12 Auburn
Alabama heads down to the Plains looking to sweep the current SEC leaders
By Bamabrave4 Feb 21, 2018, 10:00am CST
Share All sharing options for: Bama Basketball Breakdown: #12 Auburn
Marvin Gentry-USA TODAY Sports
With only four games left in the regular season, the Alabama Crimson Tide (17-10, 8-6 SEC) will make the cross-state trip to Lee County, as they attempt to sweep the 12th-ranked Auburn Tigers (23-4, 11-3 SEC). A win in Auburn would give Alabama a shot of possibly still winning the regular season conference crown, but a loss will eliminate the Tide from the chase. Either way, this will be a massive game for both teams. Just like the first meeting in Tuscaloosa, this is easily one of the most significant installments of this rivalry on the hardwood in recent memory. Hell, of all-time, even. When was the last time these two hated foes met for a basketball game with NCAA Tournament seeding, conference tournament byes, and even the regular season SEC Championship all on the line?
Bruce Pearl and Avery Johnson have both done great jobs of establishing this rivalry as one of the SEC's most significant hoops battles in 2018. At this point, it's hard to imagine Alabama missing out on the NCAA Tournament, and Auburn is a sure-fire lock to participate in the Big Dance next month. Considering Alabama has only been once in the last decade, and Auburn hasn't qualified since 2003, the fact that both will be participating in March Madness is a major achievement and milestone in this series.
The Auburn faithful have to be licking their chops to get a piece of the Tide. While the Tide football team fell to the Tigers in November, 2018 has been a much different story so far in this state. The Crimson Tide football team, of course, ended up winning the College Football Playoff anyway, and the basketball team added insult to injury with a 76-71 upset win in Coleman Coliseum, even with Collin Sexton watching from the sidelines and Donta Hall playing limited minutes.
Auburn will be ready to avenge that loss. Can Alabama pull off the sweep anyway?
The Last Meeting
Three Keys to Victory
Defend the Perimeter. Playing LSU the game prior to this one was great timing, as the Bayou Bengals are basically a poor man's version of the Auburn Tigers. Both teams are run by a dynamic, yet diminutive point guard and consist of (mostly) undersized but athletic shooters. So while defending the three-point arc was critical in the win over LSU on Saturday, it will be even more significant tonight. The Tide have had a tendency to give up open looks from three at times this season, but they should know as well as anyone how deadly Auburn can be from down-town. After all, Auburn beat Alabama in Tuscaloosa last season by shooting 15/27 from the three-point line in an 82-77 victory. If Alabama doesn't clamp down on Auburn's shooters, it could be another long night.
Free Throw Rate. Auburn is currently 13th in the country in FT% at 77.9%. They don't miss many. Considering how quick-whistled college basketball has become, it shouldn't be a surprise that they've had success this season. Alabama has improved greatly in their efficiency in this area in recent weeks, most recently shooting 18/18 in Baton Rouge on Saturday, but they've actually been beating teams pretty consistently all season in Free Throw Rate, which combines FT% with how often a team gets to the line. If Alabama can continue to get Sexton and Dazon Ingram to the charity stripe, while limiting Auburn's trips to the line, the Tide will have taken away what has been a huge advantage for Auburn all season.
Giddens, Galen, and Reece. Donta Hall will miss tonight's game as he continues to recover from his wrist surgery last week. It's a big loss for Alabama, because his size and athleticism would've given Auburn a lot of trouble in the post. However, Hall missed the game Saturday against LSU as well, and the rest of the Alabama front-court stepped up in a big way. The Tide will need a similar performance tonight. The post is still an area where Auburn, despite their high rebound and block rates, can be had. Daniel Giddens will be the biggest man on the court, if he can stay on it. He needs to stay out of foul trouble. Galin Smith and Alex Reese played argaubly their best games in Crimson and White this past weekend. If Reese can continue to stretch defenses and Smith can continue to excel with his positioning, Alabama could become really tough to beat, especially when Hall returns.
Check out this link to read the full Breakdown for the last meeting, and click here for Brent's game recap.
As mentioned, the previous meeting got a little crazy right before tip-off. Avery Johnson has always played injuries pretty close to the hip, and he sure threw everyone off the last time these two teams got together. Sexton didn't play, but Hall did. As far as we know, both should be good to go for Wednesday night. Either way, Alabama will be just fine if they can get another 27 points on 8/13 shooting from the outside from John Petty. He absolutely torched the Tigers in the first game, though his struggles away from home make it unlikely that he will come close to replicating that performance.
The main reason Alabama beat Auburn in Tuscaloosa is because they held the Tigers to 9/26 from beyond the arc. It was that game, in fact, that Alabama really turned around their three-point defense, which had been pretty ugly the first half of the season. Since then, Alabama has catapulted up to 8th overall in Kenpom's Adjusted Defensive Efficiency. The Tide will need to defend the perimeter well again tonight if they want to prevent Auburn Arena from exploding and giving the Tigers critical home-court momentum.
What to Watch For This Time
Obviously, Sexton and Hall being able to play their usual minutes makes a major difference; they are, after all, the two most important players on Alabama's team. However, this will also be Auburn's first game since they lost their starting 5, Anfernee, McElmore, for the season over the weekend when he dislocated and fractured his ankle (which was, thankfully, the extent of the injury; his foot was on backwards). That's a massive loss for an Auburn team that was already very short across the board, and very thin on true post players.
Horace Spencer, the 6'8 junior, will step in to take over McLemore's role as the one true post player in Auburn's starting line-up. He's got a ton of experience, but he's no McLemore, who had range (39.1% 3P%) and blocked shots at a ridiculous 15.7% rate. After getting dominated on the glass by Kentucky, Alabama should be looking to bounce-back with a big performance against a much, much smaller Auburn team. The Tide needs to attack the basket all night and look to get Hall as many touches around the rim as possible.
So, defend the perimeter, dominate the boards, and get the ball in the paint on offense. Oh, and try to limit the turnovers; Auburn thrives off of turning people over and getting the ball up quickly in transition for easy baskets. It's hard to imagine Alabama going on the road and finishing off the season sweep of the current SEC leaders in their home gym, but Auburn could end up looking like a completely different team post-McLemore injury. Alabama's got as good of a chance as anyone at exposing them.
The game will tip-off at 7:30 PM CST and will be televised on the SEC Network.


Modafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).
In OSA, Modafinil is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating and during treatment with Modafinil for excessive sleepiness.
100 mg: white to off-white, capsule shaped uncoated tablets, debossed with "1072" on one side and plain on the other side.
200 mg: white to off-white, capsule shaped uncoated scored tablet, debossed with "10" & "73" on either side of scoreline on one side and plain on other side.
Serious rash requiring hospitalization and discontinuation of treatment has been reported in association with the use of Modafinil.
In clinical trials of Modafinil, the incidence of rash resulting in discontinuation was approximately 0.8% (13 per 1,585) in pediatric patients (age < 17-years); these rashes included 1 case of possible Stevens - Johnson syndrome (SJS) and 1 case of apparent multi-organ hypersensitivity reaction. Several of the cases were associated with fever and other abnormalities (e.g., vomiting, leukopenia). The median time to rash that resulted in discontinuation was 13-days. No such cases were observed among 380 pediatric patients who received placebo. Modafinil is not approved for use in pediatric patients for any indication [see Use in Specific Populations (8.4)].
Rare cases of serious or life-threatening rash, including SJS, Toxic Epidermal Necrolysis (TEN), and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have been reported in adults and children in worldwide postmarketing experience. The reporting rate of TEN and SJS associated with Modafinil use, which is generally accepted to be an underestimate due to underreporting, exceeds the background incidence rate. Estimates of the background incidence rate for these serious skin reactions in the general population range between 1 to 2 cases per million-person years.
There are no factors that are known to predict the risk of occurrence or the severity of rash associated with Modafinil. Nearly all cases of serious rash associated with Modafinil occurred within 1-week to 5-weeks after treatment initiation. However, isolated cases have been reported after prolonged treatment (e.g., 3-months). Accordingly, duration of therapy cannot be relied upon as a means to predict the potential risk heralded by the first appearance of a rash.
Although benign rashes also occur with Modafinil, it is not possible to reliably predict which rashes will prove to be serious. Accordingly, Modafinil should be discontinued at the first sign of rash, unless the rash is clearly not drug-related. Discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.
Multi-organ hypersensitivity reactions, including at least one fatality in postmarketing experience, have occurred in close temporal association (median time to detection 13-days: range 4 to 33) to the initiation of Modafinil.
Although there have been a limited number of reports, multi-organ hypersensitivity reactions may result in hospitalization or be life-threatening. There are no factors that are known to predict the risk of occurrence or the severity of multi-organ hypersensitivity reactions. Signs and symptoms of this disorder were diverse; however, patients typically, although not exclusively, presented with fever and rash associated with other organ system involvement. Other associated manifestations included myocarditis, hepatitis, liver function test abnormalities, hematological abnormalities (e.g., eosinophilia, leukopenia, thrombocytopenia), pruritus, and asthenia. Because multi-organ hypersensitivity is variable in its expression, other organ system symptoms and signs, not noted here, may occur.
If a multi-organ hypersensitivity reaction is suspected, Modafinil should be discontinued. Although there are no case reports to indicate cross-sensitivity with other drugs that produce this syndrome, the experience with drugs associated with multi-organ hypersensitivity would indicate this to be a possibility.
Psychiatric adverse reactions have been reported in patients treated with Modafinil.
In the adult Modafinil controlled trials, psychiatric symptoms resulting in treatment discontinuation (at a frequency ≥ 0.3%) and reported more often in patients treated with Modafinil compared to those treated with placebo were anxiety (1%), nervousness (1%), insomnia (< 1%), confusion (< 1%), agitation (< 1%), and depression (< 1%).
Postmarketing adverse reactions associated with the use of Modafinil have included mania, delusions, hallucinations, suicidal ideation, and aggression, some resulting in hospitalization. Many, but not all, patients had a prior psychiatric history. One healthy male volunteer developed ideas of reference, paranoid delusions, and auditory hallucinations in association with multiple daily 600 mg doses of Modafinil (three times the recommended dose) and sleep deprivation. There was no evidence of psychosis 36-hours after drug discontinuation.
Caution should be exercised when Modafinil is given to patients with a history of psychosis, depression, or mania. Consideration should be given to the possible emergence or exacerbation of psychiatric symptoms in patients treated with Modafinil. If psychiatric symptoms develop in association with Modafinil administration, consider discontinuing Modafinil.
In Modafinil clinical studies, cardiovascular adverse reactions, including chest pain, palpitations, dyspnea, and transient ischemic T-wave changes on ECG occurred in three subjects in association with mitral valve prolapse or left ventricular hypertrophy. In a Canadian clinical trial, a 35-year old obese narcoleptic male with a prior history of syncopal episodes experienced a 9-second episode of asystole after 27-days of Modafinil treatment (300 mg/day in divided doses). Modafinil is not recommended in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants. Findings suggestive of mitral valve prolapse syndrome include but are not limited to ischemic ECG changes, chest pain, or arrhythmia. If new onset of any of these findings occurs, consider cardiac evaluation. Consider increased monitoring in patients with a recent history of myocardial infarction or unstable angina.
Blood pressure monitoring in short term (≤ 3-months) controlled trials showed no clinically significant changes in mean systolic and diastolic blood pressure in patients receiving Modafinil as compared to placebo. However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on Modafinil required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). The differential use was slightly larger when only studies in OSA were included, with 3.4% of patients on Modafinil and 1.1% of patients on placebo requiring such alterations in the use of antihypertensive medication. Increased monitoring of heart rate and blood pressure may be appropriate in patients on Modafinil. Caution should be exercised when prescribing Modafinil to patients with known cardiovascular disease.
Modafinil has been evaluated for safety in over 3,500 patients, of whom more than 2,000 patients with excessive sleepiness associated with OSA, SWD, and narcolepsy.
In placebo-controlled clinical trials, the most common adverse reactions (≥ 5%) associated with the use of Modafinil more frequently than placebo-treated patients were headache, nausea, nervousness, rhinitis, diarrhea, back pain, anxiety, insomnia, dizziness, and dyspepsia. The adverse reaction profile was similar across these studies.
Table 1 presents the adverse reactions that occurred at a rate of 1% or more and were more frequent in Modafinil-treated patients than in placebo-treated patients in the placebo-controlled clinical trials.
In the placebo-controlled clinical trials which compared doses of 200 mg/day, 300 mg/day, and 400 mg/day of Modafinil and placebo, the following adverse reactions were dose related: headache and anxiety.
In placebo-controlled clinical trials, 74 of the 934 patients (8%) who received Modafinil discontinued due to an adverse reaction compared to 3% of patients that received placebo. The most frequent reasons for discontinuation that occurred at a higher rate for Modafinil than placebo patients were headache (2%), nausea, anxiety, dizziness, insomnia, chest pain, and nervousness (each < 1%).
Clinical chemistry, hematology, and urinalysis parameters were monitored in the studies. Mean plasma levels of gamma glutamyltransferase (GGT) and alkaline phosphatase (AP) were found to be higher following administration of Modafinil, but not placebo. Few patients, however, had GGT or AP elevations outside of the normal range. Shifts to higher, but not clinically significantly abnormal, GGT and AP values appeared to increase with time in the population treated with Modafinil in the placebo-controlled clinical trials. No differences were apparent in alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein, albumin, or total bilirubin.
The following adverse reactions have been identified during post approval use of Modafinil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The clearance of drugs that are substrates for CYP3A4/5 (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be increased by Modafinil via induction of metabolic enzymes, which results in lower systemic exposure. Dosage adjustment of these drugs should be considered when these drugs are used concomitantly with Modafinil [see Clinical Pharmacology (12.3)].
The effectiveness of steroidal contraceptives may be reduced when used with Modafinil and for one month after discontinuation of therapy. Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with Modafinil and for one month after discontinuation of Modafinil treatment.
Blood levels of cyclosporine may be reduced when used with Modafinil. Monitoring of circulating cyclosporine concentrations and appropriate dosage adjustment for cyclosporine should be considered when used concomitantly with Modafinil.
Elimination of drugs that are substrates for CYP2C19 (e.g., phenytoin, diazepam, propranolol, omeprazole, and clomipramine) may be prolonged by Modafinil via inhibition of metabolic enzymes, with resultant higher systemic exposure. In individuals deficient in the CYP2D6 enzyme, the levels of CYP2D6 substrates which have ancillary routes of elimination through CYP2C19, such as tricyclic antidepressants and selective serotonin reuptake inhibitors, may be increased by co-administration of Modafinil. Dose adjustments of these drugs and other drugs that are substrates for CYP2C19 may be necessary when used concomitantly with Modafinil [see Clinical Pharmacology (12.3)].
More frequent monitoring of prothrombin times/INR should be considered whenever Modafinil is co-administered with warfarin [see Clinical Pharmacology (12.3)].
Caution should be used when concomitantly administering MAO inhibitors and Modafinil.
There are no adequate and well-controlled studies of Modafinil in pregnant women. Intrauterine growth restriction and spontaneous abortion have been reported in association with Modafinil (a mixture of R-and S-Modafinil) and arModafinil (the R-enantiomer of Modafinil). Although the pharmacology of Modafinil is not identical to that of the sympathomimetic amines, it does share some pharmacologic properties with this class. Certain of these drugs have been associated with intrauterine growth restriction and spontaneous abortions. Whether the cases reported with Modafinil are drug-related is unknown. In studies of Modafinil and arModafinil conducted in rats (Modafinil, arModafinil) and rabbits (Modafinil), developmental toxicity was observed at clinically relevant plasma exposures. Modafinil should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Modafinil (50 mg/kg/day, 100 mg/kg/day, or 200 mg/kg/day) administered orally to pregnant rats throughout organogenesis caused, in the absence of maternal toxicity, an increase in resorptions and an increased incidence of visceral and skeletal variations in the offspring at the highest dose tested. The higher no-effect dose for embryofetal developmental toxicity in rats (100 mg/kg/day) was associated with a plasma Modafinil AUC less than that in humans at the recommended human dose (RHD) of Modafinil (200 mg/day). However, in a subsequent study of up to 480 mg/kg/day of Modafinil, no adverse effects on embryofetal development were observed. Oral administration of arModafinil (60 mg/kg/day, 200 mg/kg/day, or 600 mg/kg/day) to pregnant rats throughout organogenesis resulted in increased incidences of fetal visceral and skeletal variations and decreased fetal body weight at the highest dose tested. The highest no-effect dose for embryofetal developmental toxicity in rats (200 mg/kg/day) was associated with a plasma arModafinil AUC less than that in humans at the RHD of Modafinil.
Modafinil administered orally to pregnant rabbits throughout organogenesis at doses of up to 100 mg/kg/day had no effect on embryofetal development; however, the doses used were too low to adequately assess the effects of Modafinil on embryofetal development. In a subsequent developmental toxicity study evaluating doses of 45 mg/kg/day, 90 mg/kg/day, and 180 mg/kg/day in pregnant rabbits, the incidences of fetal structural alterations and embryofetal death were increased at the highest dose. The highest no-effect dose for developmental toxicity (100 mg/kg/day) was associated with a plasma Modafinil AUC similar to that in humans at the RHD of Modafinil.
Modafinil administration to rats throughout gestation and lactation at oral doses of up to 200 mg/kg/day resulted in decreased viability in the offspring at doses greater than 20 mg/kg/day, a dose resulting in a plasma Modafinil AUC less than that in humans at the RHD of Modafinil. No effects on postnatal developmental and neurobehavioral parameters were observed in surviving offspring.
A pregnancy registry has been established to collect information on the pregnancy outcomes of women exposed to Modafinil. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-866-404-4106 (toll free).
Safety and effectiveness in pediatric patients have not been established. Modafinil is not approved in this population for any indication.
Serious skin rashes, including erythema multiforme major (EMM) and Stevens-Johnson Syndrome (SJS) have been associated with Modafinil use in pediatric patients [see Warnings and Precautions (5.1)].
In a controlled 6-week study, 165 pediatric patients (aged 5-years to 17-years) with narcolepsy were treated with Modafinil (n=123), or placebo (n=42). There were no statistically significant differences favoring Modafinil over placebo in prolonging sleep latency as measured by MSLT, or in perceptions of sleepiness as determined by the clinical global impression-clinician scale (CGI-C).
In the controlled and open-label clinical studies, treatment emergent adverse reactions of the psychiatric and nervous system included Tourette's syndrome, insomnia, hostility, increased cataplexy, increased hypnagogic hallucinations, and suicidal ideation. Transient leukopenia, which resolved without medical intervention, was also observed. In the controlled clinical study, 3 of 38 girls, ages 12 or older, treated with Modafinil experienced dysmenorrhea compared to 0 of 10 girls who received placebo.
There were three 7-week to 9-week, double-blind, placebo-controlled, parallel group studies in children and adolescents (aged 6-years to 17-years) with Attention-Deficit Hyperactivity Disorder (ADHD). Two of the studies were flexible-dose studies (up to 425 mg/day), and the third was a fixed-dose study (340 mg/day for patients < 30 kg and 425 mg/day for patients ≥ 30 kg). Although these studies showed statistically significant differences favoring Modafinil over placebo in reducing ADHD symptoms as measured by the ADHD-RS (school version), there were 3 cases of serious rash including one case of possible SJS among 933 patients exposed to Modafinil in this program. Modafinil is not approved for use in treating ADHD.
The abuse potential of Modafinil (200 mg, 400 mg, and 800 mg) was assessed relative to methylphenidate (45 mg and 90 mg) in an inpatient study in individuals experienced with drugs of abuse. Results from this clinical study demonstrated that Modafinil produced psychoactive and euphoric effects and feelings consistent with other scheduled CNS stimulants (methylphenidate).
In clinical trials, a total of 151 protocol-specified doses ranging from 1,000 mg/day to 1,600 mg/day (5-times to 8-times the recommended daily dose of Modafinil) have been administered to 32 subjects, including 13 subjects who received doses of 1,000 mg/day or 1,200 mg/day for 7 to 21 consecutive days. In addition, several intentional acute overdoses occurred; the two largest being 4,500 mg and 4,000 mg taken by two subjects participating in foreign depression studies. None of these study subjects experienced any unexpected or life-threatening effects. Adverse reactions that were reported at these doses included excitation or agitation, insomnia, and slight or moderate elevations in hemodynamic parameters. Other observed high-dose effects in clinical studies have included anxiety, irritability, aggressiveness, confusion, nervousness, tremor, palpitations, sleep disturbances, nausea, diarrhea, and decreased prothrombin time.
From postmarketing experience, there have been reports of fatal overdoses involving Modafinil alone or in combination with other drugs. Symptoms most often accompanying Modafinil overdose, alone or in combination with other drugs have included insomnia; central nervous system symptoms such as restlessness, disorientation, confusion, agitation, anxiety, excitation, and hallucination; digestive changes such as nausea and diarrhea; and cardiovascular changes such as tachycardia, bradycardia, hypertension, and chest pain.
Cases of accidental ingestion/overdose have been reported in children as young as 11-months of age. The highest reported accidental ingestion on a mg/kg basis occurred in a three-year-old boy who ingested 800 mg to 1,000 mg (50 mg/kg to 63 mg/kg) of Modafinil. The child remained stable. The symptoms associated with overdose in children were similar to those observed in adults.
No specific antidote exists for the toxic effects of a Modafinil overdose. Such overdoses should be managed with primarily supportive care, including cardiovascular monitoring.
Modafinil is a wakefulness-promoting agent for oral administration. Modafinil is a racemic compound. The chemical name for Modafinil is 2-[(diphenylmethyl)sulfinyl]acetamide. The molecular formula is C15H15NO2S and the molecular weight is 273.35.
Modafinil, USP is a white to almost white, crystalline powder that is practically insoluble in water and cyclohexane. It is sparingly to slightly soluble in methanol and acetone.
Modafinil tablets, USP contain 100 mg or 200 mg of Modafinil, USP and the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and pregelatinized starch.
Product complies with USP dissolution test 2.
Modafinil is a 1:1 racemic compound, whose enantiomers have different pharmacokinetics (e.g., the half-life of R-Modafinil is approximately three times that of S-Modafinil in adult humans). The enantiomers do not interconvert. At steady state, total exposure to R-Modafinil is approximately three times that for S-Modafinil. The trough concentration (Cmin,ss) of circulating Modafinil after once daily dosing consists of 90% of R-Modafinil and 10% of S-Modafinil. The effective elimination half-life of Modafinil after multiple doses is about 15-hours. The enantiomers of Modafinil exhibit linear kinetics upon multiple dosing of 200 mg/day to 600 mg/day once daily in healthy volunteers. Apparent steady states of total Modafinil and R-Modafinil are reached after 2-days to 4-days of dosing.
Modafinil is readily absorbed after oral administration, with peak plasma concentrations occurring at 2-hours to 4-hours. The bioavailability of Modafinil tablets is approximately equal to that of an aqueous suspension. The absolute oral bioavailability was not determined due to the aqueous insolubility (< 1 mg/mL) of Modafinil, which precluded intravenous administration. Food has no effect on overall Modafinil bioavailability; however, time to reach peak concentration (tmax) may be delayed by approximately one hour if taken with food.
Modafinil has an apparent volume of distribution of approximately 0.9 L/kg. In human plasma, in vitro, Modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin. The potential for interactions of Modafinil with highly protein-bound drugs is considered to be minimal.
Metabolism occurs through hydrolytic deamidation, S-oxidation, aromatic ring hydroxylation, and glucuronide conjugation. Less than 10% of an administered dose is excreted as the parent compound. In a clinical study using radiolabeled Modafinil, a total of 81% of the administered radioactivity was recovered in 11-days post-dose, predominantly in the urine (80% vs. 1% in the feces). The largest fraction of the drug in urine was Modafinil acid, but at least six other metabolites were present in lower concentrations. Only two metabolites reach appreciable concentrations in plasma, i.e., Modafinil acid and Modafinil sulfone. In preclinical models, Modafinil acid, Modafinil sulfone, 2-[(diphenylmethyl)sulfonyl]acetic acid and 4-hydroxy Modafinil, were inactive or did not appear to mediate the arousal effects of Modafinil.
In adults, decreases in trough levels of Modafinil have sometimes been observed after multiple weeks of dosing, suggesting auto-induction, but the magnitude of the decreases and the inconsistency of their occurrence suggest that their clinical significance is minimal. Significant accumulation of Modafinil sulfone has been observed after multiple doses due to its long elimination half-life of 40-hours. Auto-induction of metabolizing enzymes, most importantly cytochrome P-450 CYP3A4, has also been observed in vitro after incubation of primary cultures of human hepatocytes with Modafinil and in vivo after extended administration of Modafinil at 400 mg/day.
A slight decrease (approximately 20%) in the oral clearance (CL/F) of Modafinil was observed in a single dose study at 200 mg in 12 subjects with a mean age of 63-years (range 53-years to 72-years), but the change was considered not likely to be clinically significant. In a multiple dose study (300 mg/day) in 12 patients with a mean age of 82-years (range 67-years to 87-years), the mean levels of Modafinil in plasma were approximately two times those historically obtained in matched younger subjects. Due to potential effects from the multiple concomitant medications with which most of the patients were being treated, the apparent difference in Modafinil pharmacokinetics may not be attributable solely to the effects of aging. However, the results suggest that the clearance of Modafinil may be reduced in the elderly [see Dosage and Administration (2.4) and Use in Specific Populations (8.5)].
The pharmacokinetics and metabolism of Modafinil were examined in patients with cirrhosis of the liver (6 men and 3 women). Three patients had stage B or B+ cirrhosis and 6 patients had stage C or C+ cirrhosis (per the Child-Pugh score criteria). Clinically 8 patients of 9 patients were icteric and all had ascites. In these patients, the oral clearance of Modafinil was decreased by about 60% and the steady state concentration was doubled compared to normal patients [see Dosage and Administration (2.3) and Use in Specific Populations (8.6)].
The existence of multiple pathways for Modafinil metabolism, as well as the fact that a non-CYP-related pathway is the most rapid in metabolizing Modafinil, suggest that there is a low probability of substantive effects on the overall pharmacokinetic profile of Modafinil due to CYP inhibition by concomitant medications. However, due to the partial involvement of CYP3A enzymes in the metabolic elimination of Modafinil, co-administration of potent inducers of CYP3A4/5 (e.g., carbamazepine, phenobarbital, rifampin) or inhibitors of CYP3A4/5 (e.g., ketoconazole, erythromycin) could alter the plasma concentrations of Modafinil.
In vitro data demonstrated that Modafinil is a weak inducer of CYP3A activity in a concentration-related manner. Therefore, the blood levels and effectiveness of drugs that are substrates for CYP3A enzymes (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be reduced after initiation of concomitant treatment with Modafinil [see Drug Interactions (7)] .
Ethinyl Estradiol - Administration of Modafinil to female volunteers once daily at 200 mg/day for 7-days followed by 400 mg/day for 21-days resulted in a mean 11% decrease in mean Cmax and 18% decrease in mean AUC0-24 of ethinyl estradiol (EE2; 0.035 mg; administered orally with norgestimate). There was no apparent change in the elimination rate of ethinyl estradiol.
Triazolam - In the drug interaction study between Modafinil and ethinyl estradiol (EE2), on the same days as those for the plasma sampling for EE2 pharmacokinetics, a single dose of triazolam (0.125 mg) was also administered. Mean Cmax and AUC0-∞ of triazolam were decreased by 42% and 59%, respectively, and its elimination half-life was decreased by approximately an hour after the Modafinil treatment.
Cyclosporine - One case of an interaction between Modafinil and cyclosporine, a substrate of CYP3A4, has been reported in a 41-year old woman who had undergone an organ transplant. After one month of administration of 200 mg/day of Modafinil, cyclosporine blood levels were decreased by 50%. The interaction was postulated to be due to the increased metabolism of cyclosporine, since no other factor expected to affect the disposition of the drug had changed.
Midazolam - In a clinical study, concomitant administration of arModafinil 250 mg resulted in a reduction in systemic exposure to midazolam by 32% after a single oral dose (5 mg) and 17% after a single intravenous dose (2 mg).
Quetiapine - In a separate clinical study, concomitant administration of arModafinil 250 mg with quetiapine (300 mg to 600 mg daily doses) resulted in a reduction in the mean systemic exposure of quetiapine by approximately 29%.
In vitro data demonstrated that Modafinil produced an apparent concentration-related suppression of expression of CYP2C9 activity suggesting that there is a potential for a metabolic interaction between Modafinil and the substrates of this enzyme (e.g., S-warfarin and phenytoin) [see Drug Interactions (7)] .
Warfarin: Concomitant administration of Modafinil with warfarin did not produce significant changes in the pharmacokinetic profiles of R-and S-warfarin. However, since only a single dose of warfarin was tested in this study, an interaction cannot be ruled out [see Drug Interactions (7)] .
In vitro data demonstrated that Modafinil is a reversible inhibitor of CYP2C19 activity. CYP2C19 is also reversibly inhibited, with similar potency, by a circulating metabolite, Modafinil sulfone. Although the maximum plasma concentrations of Modafinil sulfone are much lower than those of parent Modafinil, the combined effect of both compounds could produce sustained partial inhibition of the enzyme. Therefore, exposure to some drugs that are substrates for CYP2C19 (e.g., phenytoin, diazepam, propranolol, omeprazole, and clomipramine) may be increased when used concomitantly with Modafinil [see Drug Interactions (7)] .
CYP2C19 also provides an ancillary pathway for the metabolism of certain tricyclic antidepressants (e.g., clomipramine and desipramine) and selective serotonin reuptake inhibitors that are primarily metabolized by CYP2D6. In tricyclic-treated patients deficient in CYP2D6 (i.e., those who are poor metabolizers of debrisoquine; 7 % to 10% of the Caucasian population; similar or lower in other populations), the amount of metabolism by CYP2C19 may be substantially increased. Modafinil may cause elevation of the levels of the tricyclics in this subset of patients[see Drug Interactions (7)] .
Carcinogenicity studies were conducted in which Modafinil (a mixture of R-and S-Modafinil) was administered in the diet to mice for 78-weeks and to rats for 104-weeks at doses of 6 mg/kg/day, 30 mg/kg/day, and 60 mg/kg/day. The highest doses studied were associated with plasma Modafinil exposures (AUC) less than that in humans at the recommended human dose (RHD) of Modafinil (200 mg/day). There was no evidence of tumorigenesis associated with Modafinil administration in these studies. However, the mouse study was inadequate because the high dose was not a maximum tolerated dose (MTD). In a mouse carcinogenicity study in which arModafinil (the R-enantiomer of Modafinil) was administered at oral doses of up to 300 mg/kg/day in males and 100 mg/kg/day in females for approximately 2-years, no tumorigenic effects were observed. The highest doses studied, which were considered MTDs, were associated with plasma arModafinil exposures less than (females) or 2-times (males) that in humans at the RHD of Modafinil.
Oral administration of Modafinil (doses of up to 480 mg/kg/day) to male and female rats prior to and throughout mating, and continuing in females through day 7 of gestation produced an increase in the time to mate at the highest dose; no effects were observed on other fertility or reproductive parameters. The no-effect dose of 240 mg/kg/day was associated with a plasma Modafinil AUC less than that in humans at the RHD of Modafinil.
The effectiveness of Modafinil in improving wakefulness in adult patients with excessive sleepiness associated with narcolepsy was established in two US 9-week, multi-center, placebo-controlled, parallel-group, double-blind studies of outpatients who met the criteria for narcolepsy. A total of 558 patients were randomized to receive Modafinil 200 mg/day or 400 mg/day, or placebo. The criteria for narcolepsy include either: 1) recurrent daytime naps or lapses into sleep that occur almost daily for at least three months, plus sudden bilateral loss of postural muscle tone in association with intense emotion (cataplexy); or 2) a complaint of excessive sleepiness or sudden muscle weakness with associated features: sleep paralysis, hypnagogic hallucinations, automatic behaviors, disrupted major sleep episode; and polysomnography demonstrating one of the following: sleep latency less than 10-minutes or rapid eye movement (REM) sleep latency less than 20-minutes. For entry into these studies, all patients were required to have objectively documented excessive daytime sleepiness, via a Multiple Sleep Latency Test (MSLT) with two or more sleep onset REM periods and the absence of any other clinically significant active medical or psychiatric disorder. The MSLT, an objective polysomnographic assessment of the patient's ability to fall asleep in an unstimulating environment, measured latency (in minutes) to sleep onset averaged over 4 test sessions at 2-hour intervals. For each test session, the subject was told to lie quietly and attempt to sleep. Each test session was terminated after 20-minutes if no sleep occurred or 15-minutes after sleep onset.
The MWT measures latency (in minutes) to sleep onset averaged over 4 test sessions at 2-hour intervals following nocturnal polysomnography. For each test session, the subject was asked to attempt to remain awake without using extraordinary measures. Each test session was terminated after 20-minutes if no sleep occurred or 10-minutes after sleep onset. The CGI-C is a 7-point scale, centered at No Change, and ranging from Very Much Worse to Very Much Improved. Patients were rated by evaluators who had no access to any data about the patients other than a measure of their baseline severity. Evaluators were not given any specific guidance about the criteria they were to apply when rating patients.
Both studies demonstrated improvement in objective and subjective measures of excessive daytime sleepiness for both the 200 mg and 400 mg doses compared to placebo. Patients treated with Modafinil showed a statistically significantly enhanced ability to remain awake on the MWT at each dose compared to placebo at final visit (Table 2). A statistically significantly greater number of patients treated with Modafinil at each dose showed improvement in overall clinical condition as rated by the CGI-C scale at final visit (Table 3).
Nighttime sleep measured with polysomnography was not affected by the use of Modafinil.
The effectiveness of Modafinil in improving wakefulness in patients with excessive sleepiness associated with OSA was established in two multi-center, placebo-controlled clinical studies of patients who met the criteria for OSA. The criteria include either: 1) excessive sleepiness or insomnia, plus frequent episodes of impaired breathing during sleep, and associated features such as loud snoring, morning headaches and dry mouth upon awakening; or 2) excessive sleepiness or insomnia and polysomnography demonstrating one of the following: more than five obstructive apneas, each greater than 10-seconds in duration, per hour of sleep and one or more of the following: frequent arousals from sleep associated with the apneas, bradytachycardia, and arterial oxygen desaturation in association with the apneas. In addition, for entry into these studies, all patients were required to have excessive sleepiness as demonstrated by a score ≥ 10 on the Epworth Sleepiness Scale (ESS), despite treatment with continuous positive airway pressure (CPAP). Evidence that CPAP was effective in reducing episodes of apnea/hypopnea was required along with documentation of CPAP use.
In the first study, a 12-week trial, a total of 327 patients with OSA were randomized to receive Modafinil 200 mg/day, Modafinil 400 mg/day, or matching placebo. The majority of patients (80%) were fully compliant with CPAP, defined as CPAP use greater than 4-hours/night on > 70% of nights. The remainder were partially CPAP compliant, defined as CPAP use < 4-hours/night on > 30% of nights. CPAP use continued throughout the study. The primary measures of effectiveness were 1) sleep latency, as assessed by the Maintenance of Wakefulness Test (MWT) and 2) the change in the patient's overall disease status, as measured by the Clinical Global Impression of Change (CGI-C) at the final visit [see Clinical Studies (14.1) for a description of these measures].
Patients treated with Modafinil showed a statistically significant improvement in the ability to remain awake compared to placebo-treated patients as measured by the MWT at final visit (Table 2). A statistically significant greater number of patients treated with Modafinil showed improvement in overall clinical condition as rated by the CGI-C scale at final visit (Table 3). The 200 mg and 400 mg doses of Modafinil produced statistically significant effects of similar magnitude on the MWT, and also on the CGI-C.
In the second study, a 4-week trial, 157 patients with OSA were randomized to receive Modafinil 400 mg/day or placebo. Documentation of regular CPAP use (at least 4-hours/night on 70% of nights) was required for all patients. The primary measure of effectiveness was the change from baseline on the ESS at final visit. The baseline ESS scores for the Modafinil and placebo groups were 14.2 and 14.4, respectively. At week 4, the ESS was reduced by 4.6 in the Modafinil group and by 2 in the placebo group, a difference that was statistically significant.
The effectiveness of Modafinil in improving wakefulness in patients with excessive sleepiness associated with SWD was demonstrated in a 12-week placebo-controlled clinical trial. A total of 209 patients with chronic SWD were randomized to receive Modafinil 200 mg/day or placebo. All patients met the criteria for chronic SWD. The criteria include: 1) either, a) a primary complaint of excessive sleepiness or insomnia which is temporally associated with a work period (usually night work) that occurs during the habitual sleep phase, or b) polysomnography and the MSLT demonstrate loss of a normal sleep-wake pattern (i.e., disturbed chronobiological rhythmicity); and 2) no other medical or mental disorder accounts for the symptoms, and 3) the symptoms do not meet criteria for any other sleep disorder producing insomnia or excessive sleepiness (e.g., time zone change [jet lag] syndrome).
It should be noted that not all patients with a complaint of sleepiness who are also engaged in shift work meet the criteria for the diagnosis of SWD. In the clinical trial, only patients who were symptomatic for at least 3-months were enrolled.
Enrolled patients were also required to work a minimum of 5 night shifts per month, have excessive sleepiness at the time of their night shifts (MSLT score < 6-minutes), and have daytime insomnia documented by a daytime polysomnogram.
The primary measures of effectiveness were 1) sleep latency, as assessed by the MSLT performed during a simulated night shift at the final visit and 2) the change in the patient's overall disease status, as measured by the CGI-C at the final visit [see Clinical Studies (14.1) for a description of these measures.].
Patients treated with Modafinil showed a statistically significant prolongation in the time to sleep onset compared to placebo-treated patients, as measured by the nighttime MSLT at final visit (Table 2). A statistically significant greater number of patients treated with Modafinil showed improvement in overall clinical condition as rated by the CGI-C scale at final visit (Table 3).
Daytime sleep measured with polysomnography was not affected by the use of Modafinil.
Store at 20°C to 25°C (68°F to 77° F). [See USP Controlled Room Temperature].
Advise patients to stop taking Modafinil and to notify their physician right away if they develop a rash, hives, mouth sores, blisters, peeling skin, trouble swallowing or breathing, or a related allergic phenomenon.
Advise patients not to alter their previous behavior with regard to potentially dangerous activities (e.g., driving, operating machinery) or other activities requiring appropriate levels of wakefulness, until and unless treatment with Modafinil has been shown to produce levels of wakefulness that permit such activities. Advise patients that Modafinil is not a replacement for sleep.
Advise patients to stop taking Modafinil and contact their physician right away if they experience chest pain, rash, depression, anxiety, or signs of psychosis or mania.
Advise patients to notify their physician if they become pregnant or intend to become pregnant during therapy. Caution patients regarding the potential increased risk of pregnancy when using steroidal contraceptives (including depot or implantable contraceptives) with Modafinil and for one month after discontinuation of therapy.
Advise patients to notify their physician if they are breastfeeding an infant.
Advise patients to inform their physician if they are taking, or plan to take, any prescription or over-the-counter drugs, because of the potential for interactions between Modafinil and other drugs.
Advise patients that the use of Modafinil in combination with alcohol has not been studied. Advise patients that it is prudent to avoid alcohol while taking Modafinil.
If you have a severe rash with Modafinil, stopping the medicine may not keep the rash from becoming life-threatening or causing you to be permanently disabled or disfigured.
It is not known if Modafinil tablets are safe or effective in children under 17-years of age.
obstructive sleep apnea (OSA). Modafinil tablets are used to treat excessive sleepiness, but not the obstruction or medical condition that is causing OSA. You should talk with your doctor about treatments for OSA before you start taking Modafinil tablets and during treatment with Modafinil. Modafinil tablets do not take the place of treatments that your doctor has prescribed for OSA. It is important that you continue to use these treatments as prescribed by your doctor.
Modafinil tablets are a federally controlled substance (C-IV) because it can be abused or lead to dependence. Keep Modafinil tablets in a safe place to prevent misuse and abuse. Selling or giving away Modafinil tablets may harm others, and is against the law. Tell your doctor if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
are pregnant or planning to become pregnant. It is not known if Modafinil will harm your unborn baby.
There is a registry for women who become pregnant during treatment with Modafinil tablets. The purpose of this registry is to collect information about the safety of Modafinil tablets during pregnancy. Contact the registry as soon as you learn that you are pregnant, or ask your doctor to contact the registry for you. You or your doctor can get information and enroll you in the registry by calling 1-866-404-4106.
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Modafinil and many other medicines can interact with each other, sometimes causing side effects. Modafinil may affect the way other medicines work, and other medicines may affect how Modafinil works. Your dose of Modafinil or certain other medicines may need to be changed.
a hormonal birth control method, such as birth control pills, shots, implants, patches, vaginal rings, and intrauterine devices (IUDs). Hormonal birth control methods may not work while you take Modafinil. Women who use one of these methods of birth control may have a higher chance for getting pregnant while taking Modafinil, and for one month after stopping Modafinil. Talk to your doctor about birth control choices that are right for you while taking Modafinil.
Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine. Your doctor or pharmacist will tell you if it is safe to take Modafinil and other medicines together. Do not start any new medicines with Modafinil unless your doctor has told you it is okay.
People with narcolepsy or OSA usually take Modafinil tablets 1-time each day in the morning.
People with SWD usually take Modafinil tablets about 1-hour before their work shift.
Do not drive a car or do other dangerous activities until you know how Modafinil affects you. People with sleep disorders should always be careful about doing things that could be dangerous. Do not change your daily habits until your doctor tells you it is okay.
Some effects of Modafinil tablets on the brain are the same as other medicines called "stimulants". These effects may lead to abuse or dependence on Modafinil tablets.
Call your doctor for medical advice about side effects. You may report side effects to Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088.
Store Modafinil at room temperature between 68° F and 77° F (20°C and 25° C).
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Modafinil tablets for a condition for which it was not prescribed. Do not give Modafinil tablets to other people, even if they have the same symptoms you have. It may harm them and it is against the law.
This Medication Guide summarizes the most important information about Modafinil tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Modafinil tablets that is written for health professionals.
Inactive Ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and pregelatinized starch.


text:
[Links] 14-21 March 2017
By: Anime Feminist | March 21, 2017 | 3 Comments
Some really interesting links this week on what it means to be "Other" while living in Japan, and spotlights on some quality women in anime (real and fictional).
AniFem Round-Up
[My Fave Is Problematic] Cross Ange
A contributor makes a case for the strong lead and good, good queer subtext under the surface of this fanservice-fest.
[Throwback] Male power fantasies in Re:ZERO
Throwback posts are for linking essays on older shows that you might've missed – in this case, an article about Re:ZERO's indulgence of a male savior fantasy.
[Feature] Reimi is Unbreakable: Female empowerment in Diamond is Unbreakable
JoJo's Bizarre Adventure might predominantly be a show about beautiful men and their fashion muscles, but that doesn't mean there aren't women worth spotlighting too.
[AniFemTalk] Disability in anime and manga
Disability and the experience of being a disabled person aren't necessarily done often or well in anime – so let's spotlight the good and unpack the bad.
Beyond AniFem
How Fukushima gave rise to a new anti-racism movement (Al Jazeera)
The horrors of Fukushima awakened both virulent racism against perceived 'foreigners' (minority groups) living in Japan, as well as a movement newly aware of the need to campaign all the harder for human rights.
Hate speech in the form of vitriolic racist abuse on social media remains prolific. Some Zainichi Korean women who have become visible in the anti-racism movement even report being the targets of stalking at their workplaces and in their neighbourhoods. This has spurred activists and sympathetic politicians to advocate for legislation specifically addressing the problem of online hate speech.
Activists worry that the deep roots of discrimination in Japan go beyond hate speech. In Tokyo's 2016 gubernatorial election in July, former Zaitokukai leader Makoto Sakurai garnered around 110,000 votes. Though only a fifth place ranking, and slightly less than two percent of the popular vote, Sakurai went on to found the far-right Japan First Party the following month.
Towards a True Children's Cinema: on 'My Neighbor Totoro' (Bright Wall/Dark Room)
On how Totoro breaks from the traditional "hero's journey" structure mandated in popular film, and succeeds.
My Neighbor Totoro is a genuine children's film, attuned to child psychology. Satsuki and Mei move and speak like children: they run and romp, giggle and yell. The sibling dynamic is sensitively rendered: Satsuki is eager to impress her parents but sometimes succumbs to silliness, while Mei is Satsuki's shadow and echo (with an independent streak). But perhaps most uniquely, My Neighbor Totoro follows children's goals and concerns. Its protagonists aren't given a mission or a call to adventure—in the absence of a larger drama, they create their own, as children in stable environments do. They play.
How My Race Defined My Gender When I Lived In Japan (Bust)
An account of the author's experience living in Japan as a Black woman, and how she was often read as male because of Japanese standards of femininity.
What was happening here? No one had prepared me to deal with this, but I had my own theories as to why people were so confused. Physically speaking, I was so outside their standard definition of femininity. Most of the Japanese women I met had fair skin and spent a fair amount of time trying to keep it that way.
Fairness suggested beauty, aristocracy and grace. Darkness suggested peasantry, hours of toiling in the fields and blue collared farmers — most of whom were male. Since I was tall and liked doing pushups in my living room every day, I realized I had the build and the complexion of a man who tilled soil all of his life. But these theories would not help me in the classroom. The kids continued to question.
Japan just elected its first trans man into public office (Pink News)
A news item to celebrate the recent election of Tomoya Hosoda as a councilor in Iruta.
In a profile for Out in Japan, Hosoda explained that he will be working for LGBT rights as well as improving the lives of the elderly and disabled.
He said: "For me, coming out is just the starting line.
"It is now time to build a foundation for the people who need to move forward. Some walls can not be overcome by one person. We have to work together, and help each other out."
Legend of the Overfiend (Urotsukidoji) – Dicks Fall, Everyone Dies (Trash & Treasures)
A podcast retrospective on the infamous granddaddy of the tentacle porn subgenre. It…it's actually kind of a boring movie, as it turns out?
Finding Yourself in Fandom (Uncanny Magazine)
An essay on the experience of being a person of color in geek circles.
Discussing race and identity has never been easy for me; my childhood heavily emphasized assimilation and "not seeing race." The irony is that despite (or perhaps because of) the many problems regarding representation in fandom and geek culture, it's in large part because of my participation in fandom that I've at long last found my footing in exploring what it means for me to be Asian American, and reconnecting with my roots as a Filipina.
WHAT'S THE DEAL WITH THE IDOLM@STER SIDEM'S ANIME STAFF? (Sakuga Blog)
It's always nice to see titles go to up-and-coming female directors. Even if it's an A-1 joint with some foreboding production issues.
Miyuki Kuroki taking up a directorial position comes as no surprise; she was my #1 prediction not only due to her well documented love of Jupiter, but her recent venture as sub-director in Occultic;Nine felt like a stepping stone being used to prepare her for bigger things.
Scum's Wish: Tainted Teenage Love (Anime News Network)
On the fact that while Scum's Wish might come from the same mold as End of Evangelion or Flowers of Evil, but it maintains far less of a clinical distance from its cast and their struggles.
Most importantly, Scum's Wish is not out to criticize. It doesn't intend to coldly analyze its characters, to indict or humiliate them, or to study them as nostalgic artifacts from the writer's bygone history. Hanabi, Mugi, and Sanae are actively trying to navigate the stormy waters of young adulthood, and Scum's Wish invites its audience to take that journey with them in the present tense.
Finding a family in Japan's foreign drag scene (The Japan Times)
Drag is a complicated subject in the Western queer community, and this article interviews only foreigners who've carved themselves a place in Japan's drag scene – but while this article feels a touch incomplete, it's also intriguing as a look at intersections of Otherness.
Even if drag is not always feminist, it definitely has a radical side to it for Judd. He has been attacked several times on the streets of Osaka because of the way he dresses. Once, a man crawled between his legs with a camera while he was waiting at a station. However, he is adamant that incidents like these will not stop him dressing in drag.
On the contrary, he says: "Definitely it wouldn't stop me from doing shows. I have actually done shows about it, about rape and abuse. Those experiences kind of blend into the work I do."
But doing drag is safer here, the three agree, than in their own countries.
My Favorite Anime: Puella Magi Madoka Magica (Little Anime Blog)
One writer speaks about what Puella Magi Madoka Magica has meant to her as a queer anime fan.
Before I moved to different kinds of theory in college, I had mere ideas of what my sexuality and identity meant to me as I grew into an adult. Suffice it to say, as I am still an otaku today, anime was one of the ways I figured out a lot about myself and what I was feeling before I could critically analyse it. For me, Magi Madoka was one of those series that shifted my thinking.
BONUS: The Sparkling Heart of Darkness: Madoka's message of hope for mature audiences (Little Anime Blog)
One of our own contributors wrote a thoughtful response to our recent post on dark magical girls (warning: spoilers).
If we take Madoka as a psychological horror, its problematic nature becomes less surprising. Le's response conjures the practicality of horror as a means of exposing ourselves to our deepest fears, about the world around us and ourselves. Insignificance, an inability to free a terrifying world from suffering, underpins Madoka's leap into becoming a magical girl on the promise of a granted wish from Kyubey. It's a grim truth that wishes can only come true by giving up something of oneself.
AniFem Community
[AniFemTalk] Which are the best representations of disability in anime/manga? https://t.co/KpkSyzeGVY pic.twitter.com/ZXftTK9RwD
— AniFem (@AnimeFeminist) March 20, 2017
We asked about portrayals of disability on Twitter as well, and got some great answers.
@AnimeFeminist As someone with Asperger's my favourite depiction of disability in manga is "With the Light: Raising an Autistic Child".
— Ian Wolf (@ianwolf) March 20, 2017
@AnimeFeminist I really dig Nicolas Brown from Gangsta personally. 🙂 pic.twitter.com/q6oVqznzxH
— Dre (@dre_lasana) March 20, 2017
@AnimeFeminist REAL beats Vagabond as my favorite work by Takehiko Inoue, following the members of a wheelchair basketball team. pic.twitter.com/Cuz3Vb17SS
— Peter Fobian (@PeterFobian) March 20, 2017
@AnimeFeminist anime-planet has a p comprehensive list of disabled charas, tho idk how well they're all written https://t.co/qa3aBqxhFq
— to the girl almighty (@blusocket) March 20, 2017
Commenters also brought up more allegorical portrayals of disability, such as Interviews with Monster Girls (which we noted in our season premiere review and first podcast) and My Hero Academia.
An interesting take on My Hero Academia! Any thoughts on quirklessness as disability? https://t.co/VjbhWNoZnY
There are, as always, thought-provoking comments on the original post itself too, so feel free to join in the conversation!
We are just $38 in pledges away from being able to produce weekly podcasts, paying an editor $15 an hour for their work! If you appreciate what we do, believe in paying people fairly, and can spare just $1 a month please become a patron today!
About the Author : Anime Feminist
Read more articles from Anime Feminist
Weekly Round-Up, 29 December 2021 – 4 January 2022: Heike History, Abortion Access, and Square Enix NFT Breakdown
Weekly Round-Up, 24-30 November 2021: Female Animator Roundtable, Game Localization Talk, and Relatable Komi-san Anxiety


The celebration will kick off with a Run Rally (Fun Run), followed by a Craft Show, Show & Shine Car Show, 'Food in the Park', concluding with a Movie/Popcorn at the Center Hall and Street Dance. We plan to showcase the history of Knox County by offering tours of the Knox County Courthouse Saturday afternoon. Sunday will feature 'Church in the Park' followed by rolls & coffee. The weekend will conclude with a Grand Parade featuring entries from all Knox County communities.


text:
Jobs by Position
January 2020 Job Listing for "Solutions Jobs"
Search result for Solutions Jobs in United States of America (USA) are listed bellow. Jobzed.com is your partner for searching job vacancies and building up a career in United States of America which also includes areas of USA like New York, California, Florida, Pennsylvania, Illinois, Florida, Ohio and Texas. You can search more similar jobs using our website for you to start working on your career.
Vice President Customer Success - DevOps - Remote
Company: Global DevOps Continuous Testing Company
Location: Remote
Enhance Effectiveness and Efficiency Through Technology by Support systems, Reference and advocacy solutions. VP of Customer Success - DevOps - Remote*.
Healthcare Fraud, Waste and Abuse Clinical Reviewer - Remote
Company: Integrity Advantage
Ability to quickly adapt to different anti-fraud technology solutions. Healthcare Fraud, Waste and Abuse Clinical Reviewer – Remote *.
Enrollment/Eligibility Business Analyst
Company: VB
New and existing business operating models and innovative approaches to solutions. Capable of investigating and familiarizing the technical architecture of…
Diagnostics Solutions Consultant – San Diego
Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Building on 65 years of experience, we deliver quality medicines and vaccines, complemented by diagnostic products and genetic tests and supported by a range of services.
Diagnostic Solutions Consultant – Northern NJ/PA
Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Building on 65 years of experience, we deliver quality medicines and vaccines, complemented by diagnostic products and genetic tests and supported by a range of services. We are working every day to better understand and address the real-world challenges faced by those who raise and care for animals in ways they find truly relevant.Our name, Zoetis (z-EH-tis), has its root in zo, familiar in words such as zoo and zoology and derived from zoetic, meaning "pertaining to life." It signals our company"s dedication to supporting the veterinarians and livestock producers everywhere who raise and care for the farm and companion animals on which we all depend on.Zoetis is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status or any other protected classification.
Diagnostics Solutions Consultant – Wisconsin
Diagnostics Solutions Consultant – NYC
Diagnostics Solutions Consultant – Seattle
Diagnostics Solutions Consultant – Houston
Diagnostics Solutions Consultant – OKC / W. Kansas
Diagnostics Solutions Consultant – AZ / NM
Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Building on 60 years of experience, we deliver quality medicines and vaccines, complemented by diagnostic products and genetic tests and supported by a range of services. We are working every day to better understand and address the real-world challenges faced by those who raise and care for animals in ways they find truly relevant.Our name, Zoetis (z-EH-tis), has its root in zo, familiar in words such as zoo and zoology and derived from zoetic, meaning "pertaining to life." It signals our company"s dedication to supporting the veterinarians and livestock producers everywhere who raise and care for the farm and companion animals on which we all depend on.Zoetis is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status or any other protected classification
Diagnostics Solutions Consultant – Upstate NY / W. Penn
Diagnostics Solutions Consultant – Indiana
Diagnostics Solutions Consultant – Tennessee
Diagnostics Solutions Consultant – Columbia, SC
Diagnostics Solutions Consultant – Columbia, SC or Augusta, GA
Diagnostic Solutions Consultant
Jobs in New York
Jobs in California
Jobs in Pennsylvania
Jobs in Illinois
Jobs in Ohio
Jobs in Texas
© 2020 All Rights Reserved.Jobzed - Jobs in United States of America (USA), career and employment opportunities.
Job in United States of America
Get updated on daily job vacancies!
Be updated by pressing the Facebook Like or G+1 button bellow.


text:
Includes unlimited streaming of Confessions of a Permanent Alien Opium Beater via the free Bandcamp app, plus high-quality download in MP3, FLAC and more.
Confessions of a Permanent Alien Opium Beater - Side A 40:05
Confessions of a Permanent Alien Opium Beater - Side B 39:22
Madteo (aka Matteo Ruzzon) is the perpetual outsider. An Italian producer who moved to New York City in the mid '90s during the tail end of hip-hop's golden age, he's been surreptitiously sending strange electronic missives to the fringes of underground house, techno, and hip-hop for over a decade. Everything he does skews outside of typical industry expectations and is imbued with an otherness that's by turns puckish and sinister. That includes this new hybrid beast, Confessions of a Permanent Alien Opium Beater.
Somewhere between a Dadaistic mixtape, a surreal audio collage sourced from his record collection, and sporadic interjections from Madteo's own storehouse of outlandish and intriguing productions, this 79-minute journey reveals the man's freewheeling rigor in the studio. Early on, a stoic woman intones, "We are like-minded individuals, sharing a common vision, pushing toward a world rid of color lines," which serves as Madteo's musical mission statement for what is simultaneously a critique and a celebration of his adopted country. A cavalcade of surprising voices—a profane child, a militant pro-black poet, an eccentric "millionaire," a woman under demonic possession, etc.—weaves in and out of abstract, unsettling, spacey electronic music that at times recalls DJ Spooky's similarly eerie and cryptic 1995 mix Necropolis: The Dialogic Project.
Prone to glitching, rhythmic ruptures, and end-times bass frequencies, Confessions surfs quark-infested waters with hallucinogenic logic. Fragmentation rules everything around Madteo. You will hear—among other things—Adderall-addled Danny Brown raps subsumed by mutant techno, radio ads for trance-blues masters Canned Heat, riveting noise-techno merging into lopsided hiphop reminiscent of Jan Jelinek's Exposures project, the passionate folk balladry of Lucio Battisti, the glittery soul of Billy Preston, and some of the coldest and oddest electro funk ever. Throughout, Madteo flaunts baffling, unprecedented sounds arranged in confounding configurations.
Confessions of a Permanent Alien Opium Beater is another crucial piece of a discography from one of music's most fascinating enigmas, a celestial lysergic jukebox that conjures new pleasures and deeper mysteries with each listen.
abstract beatdown dark ambient leftfield techno Los Angeles


Late fees will be added to entries after midnight, Sunday, May 13, 2018.
* After May 22nd, before registering,email the Registrar to check if maps are still available for your courses.
Team Trials Sprint Courses, SUNY Purchase, NY.
This event is organized by the ESC and hosted by HVO, and will serve as the US Team Trials for the sprint. It is open to anyone.
This event is being run as a US Team fundraiser. Net proceeds will be donated to the US Team to help defray costs of attending WOC. The fee for the sprint course is $20. We will be using SI-Air epunching and the fee to rent an SI-Air card is $5. Details on the SI-Air system will be posted and model controls will be available at the event. Regular SI cards can also be used.
Age Restrictions for the sprints: Unfortunately, due to restrictions of our permit, only those 17 years of age (as of the day of the event) and older may compete. See full details in the link below.
Middle Courses at Westmoreland Sanctuary, Mount Kisco, NY.
9:30 - 16:30 - Shuttle busses operate between Fox Lane High/Middle School and Westmoreland Sanctuary(~ 10 min. ride). Shuttles will operate at 15-20 min intervals.
10:00 - 14:00 - Registration packet pick-up at parking lot of Westmoreland Sanctuary.
11:00 - 11:40 - US Team Trials starts.
12:00 - 14:00 General public competitive starts.
The Start is 500 m away, trail walk from the Registration, Sanctuary building.
White, Yellow and Orange Recreational courses available at Westmoreland Sanctuary, starting 12:30. Separate registration and results will be handled by HVO and Westmoreland Sanctuary staff for recreational courses, inside main building.
14:30 - 16:00 Live results award ceremonies for competitive classes.
Relays at Sal J Prezioso Mountain Lakes County Park, North Salem NY.
12:00 – First leg mass start.
14:00 - First team approximate finish.
14:30 - Mass start leg 2 and 3 team members who have not run yet.
Long Courses at Sal J Prezioso Mountain Lakes County Park, North Salem NY.
7:30 Parking Open (same area as on Sunday), walk 600 meters marked route to Event Arena.
Parking at event arena is reserved for EMT and Event workers.
9:30 - 11:30 - General public competitive starts.
The Start is 200 m away from arena.
11:30 - 13:00 - Live results award ceremonies for competitive classes.
14:59 - All courses closed.
* After May 22nd, before registering, email the Registrar to check if maps are still available for your courses.
White, Yellow and Orange recreational courses will be available for novice participants on Saturday and Monday.
Adults: $12 per map, juniors (20 years and younger) $7 per map.
Scouts and other youth groups: $5 per map. Additional map for multiple people in the same group: $2 per map.
These fees includes full instruction, an electronic punch and compass rental if needed.
Medals for Saturday's Middle Courses and Monday's Long Courses and will be given to top 3 finishers in all competitive age classes. We will use live result lists to have Medal Ceremony in each competitive class as soon as 3 top places in that class are determined.
Medals and prizes will be awarded to top 3 Club Relay Teams from US or Canada in two categories: 3+ and 7+ points. Separate awards will be given to teams consisting from juniors only (M/F20 and younger) in 7+ points category.
Vegetation - predominantly open hardwood forest, with a few clearings, relatively small areas of Japanese Barberry bushes, mapped as vertical green lines. Not too many trees down from recent storms. Rootstocks are mapped using green cross symbol, only 1.5 meter or higher rootstocks are mapped.
Water features - all streams are crossable, some wetlands and marshes are well mapped and some will be marked out bounds, due to the hatching activities in the spring. Courses are designed to avoid protected wetlands.
Topography - glaciated hills with up to 100 m relative height, some steep, usually rocky slopes.
Manmade features - well developed trail and stone wall network, cairns.
•	Sanctuary's territory is surrounded by private property, clearly marked on the map in olive green, please respect private property, stay away from it.
Map - 1:10,000 scale, Sm contours for Blue, Red, Green and Orange courses. 1:7,500 for Brown, Yellow and White . First edition of this map dates to 1984, field work was done by a number of Westchester Orienteering Club volunteers with coordination and drafting by Eric Weyman. Latest version of the map was done in 2014, by Greg Balter, using Westchester County LIDAR data and Aerial Photography from 2013. Field-checking was done by Geof Connor and Greg Balter in 2015. Geof updated trail network since, at least once a year. Last time this map was used by HVO for regional JROTC Event in November of 2017.
Vegetation - predominantly open hardwood forest, few clearings, some areas of Japanese Barberry bushes, mapped as vertical green lines. Not too many trees down from recent storms. Some, relatively small areas of mountain laurel mapped as light green or second green in some cases.
Water features - all streams are crossable, wetlands and marshes are well mapped and some will be marked out bounds, due to the hatching activities in the spring. Courses are designed to avoid protected wetlands.
Rock - fair amount of cliffs and boulders of various sizes, mapped to IOF standards.
Topography - glaciated hills with up to 85 meters relative height, some steep, usually rocky slopes.
Manmade features - park has maintained trail network. Also some parts of park have stone wall network, left from farmland times.
•	Park's territory is surrounded by private property, clearly marked on the map in olive green, please respect private property, stay away from it.
Map - 1: 10,000 scale, Sm contours. Field-checking was done in 2014, by Bob Burg, using Westchester County LIDAR data and Aerial Photography from 2013. That edition of this map was used during Fall 2014 by HVO for 2 day National Classic Meet. In 2016 was redrafted by Greg Balter, in order to bring drafting standards of the map to IOF requirements. Smaller features were consolidated to improve readability on a run. Trail network updated by Geof Connor annually. Last time this map for used for WCOC/HVO Winter 2018 training series.
Camping in Yurts - Mountain Lakes.
The yurts are located close to the registration/finish area day 3.
Camping is also available in open-face lean-tos on the shore of one of the Lakes. Sleeping capacity is limited to eight people per shelter. Each shelter site has an outside grill for cooking, a designated fire ring for campfires and a picnic table. Porta-potties are also provided close to the lean-to area.
Camping should be booked directly through the WPR Reservation at (914) 864-7317.
Per OUSA 'Rules for Foot Orienteering Events', Section A.33.9, "Competitors shall not have any animals accompanying them on the course. Additionally, in order to ensure the safety of the competitors, and to avoid any possible distractions, dogs are prohibited from the Start and Finish areas, and from the arena".
We will operate shuttle busses from Fox Lane High School Parking Lot to Westmoreland Sanctuary from 10:00 until 16:00. Bus ride takes ~ 15 min.
We will have orienteering signs around the park to the location of the arena. Since parking area also serves as event Arena, please follow directions from our volunteers, responsible for parking.In case main parking lot gets full, we will direct you to auxiliary parking spots no feather than 500 m away.
We will have orienteering signs around the park to the location of the parking.
Arena is located 600m away, and walk to the arena will be blazed with streamers from the parking lot. Since, Start and Finish are very close to arena, we suggest you bring your gear with you and enjoy the show.


text:
Q: Using rsync to copy data from one Drobo (NTFS) to another Drobo (Mac OS Extended (Journaled)) I have been using Windows 2008 in Parallels on my Mac Server to serve up files to my Windows clients on the network with a USB attached Drobo (NTFS). Now I want to move these files to my Mac Drobo (Mac OS Ext) and maintain as many file attributes as possible, such as date created and modified.
Recently I learned how to copy large amounts of data using rsync on my Mac. I assume permissions will not translate, but can I use the same command to copy the data from a NTFS formatted Drobo to the Mac OS Extended Drobo and maintain file attributes/metadata?
Here's the commend I used before:
sudo rsync -va --progress /Volumes/SourceName /Volumes/DestinationName

Thank you.

A: Check out the man page for rsync. In particular, the -a (archive) option you show will invoke the -rlptgoD options.

*

*-r, --recursive (recurse into directories)

*-l, --links (copy symlinks as symlinks)

*-p, --perms (preserve permissions)

*-t, --times (preserve times)

*-g, --group (preserve group)

*-o, --owner (preserve owner (super-user only))

*-D (preserve device and special files)

Permissions can be preserved, but everything you copy will be owned by you unless you run under sudo so the -o option will take effect. Also note that without sudo, rsync gives you no special abilities to copy files that you do not have access to on the source drive.
You may also want to look at the -E option, but I don't know if it will work from an NTSF drive. Maybe it will preserve ACLs (if they exist on the source)?

redpajama_set_name: RedPajamaStackExchange


Thailand Villa 8976 is an up market and exclusive Phuket retreat.
Far from the repetitive nature of 5 star hotels, this is a unique property, a 5 star luxury experience in the privacy of your own villa.
An 8 Bedroom Private luxury Thai Villa, where each villa has a spacious master bedroom which leads to a luxurious ensuite bathroom with full size bath and shower.
The furnishings and art are of the highest quality giving you the feeling of being in your own luxury home.
Each bedroom has an outside seating area on a spacious terrace providing the ideal setting for candle lit cocktails.
Each bedroom features a king size bed and is furnished with Jim Thompson silks.
There is a staff including a cook, driver, house maid and gardener.
Breakfast can be served at a time to suit either inside your bedroom or on your own terrace over looking the pool.
Lunch and dinner can be prepared by simply requesting the day before what you would like to eat and when.
All produce will be purchased fresh from the local market.
A full massage service is only a phone call away either in the privacy of your room or on the sala over looking the pool.
Each bedroom has an excellent view of the pool and beautifully landscaped garden.
Across in the main home the living areas have the finest quality granite flooring with furnishings from Thailand and Indonesia.
Beautiful paintings and Buddha sculptures add to your feeling of peace and tranquility, the ability to rejuvenate and recharge your life force.
In front of the Ying and Yang designed pool is a relaxing sala for taking the well deserved deep tissue aroma massage or just lounging about, catching the breeze, and reading that long awaited novel.
The lounges and dining area provide excellent facilities for relaxation or entertaining with the latest in HiFi, DVD and satellite TV facilities.
Bangtao Beach, Phuket's only 5 star beach, is home to the Sheraton, Dusit, Laguna and Banyan Tree Resorts, and is only a short stroll away from the villa.
The vila is located a few miles from this golden beach and just 5 minutes drive from an array of top class restaurants and bars.
The Boat Laguna is a only a maximum of 15 minutes away.


Our youth ministry had its annual Christmas party last week.
Our student leaders are not merely decorative. They don't hold honorary titles. Instead, they have real responsibilities.
All semester long, they've led our youth ministry in an assortment of ways, during times my adult leaders and I have been present. We've offered encouragement and on occasion, corrections. We know what they're capable of.
So when we sat down to schedule our Christmas party and quite simply, ran out of potential dates on which to do so, a student leader suggested they run the Christmas party without us.
So we moved the Christmas party to someone's house so that even though there wasn't an adult leader present in the room, there was still an adult (a parent) in the house. Then we spent the next several weeks planning the Christmas party during our student leadership team meetings.
We chose games and figured out how we wanted to do the White Elephant gift exchange. Each student leader then took responsibility for one aspect of the party, including its up-front leadership. Finally, we decided what order the activities would take place in. At our final meeting before the party, our student leaders left more excited about our Christmas Party than I'd seen them in years.
The night of the party came and by all accounts, the student leaders did a great job at leading it. They welcomed people, kept things moving, and ensured people had a good time. When problems arose, they solved them… Because they had to. There was no adult leader there to bail them out. They worked together as a team and left with a newfound confidence that came from having accomplished what they set out to do.
This year, our Christmas party went off without a hitch…. And I wasn't there.
Our student leaders led… Without me.
But then I remember the point of discipleship is to train student leaders to function without us: To be able to grow in their faith, without the constant guidance of a youth pastor; To be able to lead without an adult giving them step by step instructions.
Last week, my student leaders did that.
And so this week, we're celebrating.
For more on Student Leadership, pre-order Jen's new book, Unleashing the Hidden Potential of Your Student Leaders, which will be available in April.
love this. a case study of amazing leadership.
The proof is in the pudding, which in this case is more than tasty!


Who ever came up with this idea is a genius. Love it! You did a great job on it.
That is so lovely and handy!
I ordered the book just for this pattern! It is so handy to have everything gathered already!
Now that I look at this again, I like it even more than I did before. I'm thinking "When do I not have a project (or more) going?" Never! I always have scissors, hooks and markers strewn around. Hmmm.
Oh my goodness! Great idea. Good job.


text:
December 26, 2020 Kedsta Rpt South Africa 0
SOUTH AFRICA, CAPE TOWN – Delft police in the Western Cape are on the manhunt for gang members responsible for wounding three people, including a four-year-old girl and her mother.
The incident occurred late on Friday night in the Rosendal area.
The little girl and her 26-year-old mother were caught in a crossfire when an alleged gangster chased after another man who was also hit by a bullet.
The child was wounded in her leg, while her mother was struck in the mouth.
"The circumstances surrounding a shooting incident last night [Friday] in Delft where three persons were shot and injured are under investigation. We have opened cases of attempted murder for further investigation," said police spokesperson Frederick van Wyk.
Delft Community Policing Forum chairperson, Charles George, called on the public for their assistance in tracing the suspects.
"It's actually sad that we can't even celebrate a day like Christmas without these incidents or a little girl being shot in the crossfire. Our hearts and prayers are with the family and we want to ask our community to support the law enforcement agencies," he said.
STAY UPDATED! READ: SAPS Removes 7 Members For Involvement In Corruption
Tombstone Of Senzo Meyiwa Has Been Vandalised


text:
Watch The SpaceX Falcon 9 Sea Landing Up Close In 360-Degree Video
Vincent Lanaria, Tech Times 30 April 2016, 08:04 am
Just a few weeks ago, the SpaceX Falcon 9 successfully landed on a floating platform off the coast of Florida, and those who want a closer look are in luck, as 360-degree footage of the huge event are up online.
What this entails is that viewers get front-row seats of the landing without the nasty consequence of getting burned to a crisp, which is a good thing, to be honest.
The great thing about the video is that it's viewable on every platform — on the PC, on the smartphone, on the tablet and even on a virtual reality headset. On top of that, it's available on both Facebook and YouTube to boot. That just goes to show that SpaceX wants practically every person to get a good look of Falcon 9 touching down on a sea barge from every perspective.
As expected, a ton of users already watched the whole footage in virtual reality, with the Google Cardboard or the Samsung Gear VR. Needless to say, the majority of the viewers enjoyed the experience.
Moving forward, SpaceX is targeting to repeat the feat on May 3, and other than the affair itself, what's interesting to see is whether or not there will be another 360-degree clip to look forward to.
It's also worth mentioning that the spaceflight company intends to land a spacecraft on Mars as early as 2018 too, and a virtual reality video of that experience is definitely going to be priceless. Well, that's assuming that it can get everything it needs nice and ready by then.
Do you own a Samsung Gear VR, Google Cardboard or any other virtual reality headset to view the Falcon 9 sea landing up close? If so, don't hesitate to drop by our comments section below and let us know how the entire experience was.
Don't forget to hit up the 38-second 360-degree video below too and watch the awesome landing unfold before your very eyes.
Photo: SpaceX | Flickr
Tags: SpaceX Falcon 9 Virtual Reality 360-Degree Video
Can SpaceX Land Red Dragon On Mars In 2018? Here's What It Would Take
SpaceX Announces Plan To Land Spacecraft On Mars As Soon As 2018
SpaceX Aims For Another Sea Landing With May 3 Launch
SpaceX Nails Historic Landing At Sea: Here's What's Next, According To Elon Musk
SpaceX Falcon 9 Rocket Successfully Lands On Floating Platform Off Coast Of Florida


Yesterday afternoon, when Congressman Dave Loebsack announced his retirement beginning at the end of the 116th Congress, the reality of it hit home.
Dave and I briefly discussed retirement, his and mine, over the last couple of years. He talked with everyone he met about almost anything. Last summer it became clear his days as a U.S. Congressman were numbered. I posted about it here. To put the date Jan. 3, 2021 on it brings to a conclusion an important part of my political life.
Few political events changed me as much as the Nov. 7, 2006 general election which repudiated the George W. Bush administration, changed the tone in Washington and Iowa, and paved the way for Democrats to elect Barack Obama president two years later.
That's not to say Republicans didn't become energized. With losses in 2006 and 2008, and after the Patient Protection and Affordable Care Act was signed into law March 23, 2010, they came back. Republicans successfully pushed back the Democratic tide and re-elected Terry Branstad who went on to become the longest-serving governor in U.S. history. Under the leadership of Jeff Kaufmann, who became chair of the Republican Party of Iowa in June 2014, Republicans built a political machine that's proven hard to beat. Through all of this, Dave Loebsack persisted, continued to win re-election, and remains undefeated.
Within hours of the press release, people were thanking Loebsack on social media, with some already moving on to the topic of the horse race to replace him. Four names raised yesterday are worth discussing.
If Rita Hart is interested in running for Congress, she could likely win the June 2, 2020 Democratic primary election. As our candidate for lieutenant governor in 2018, she campaigned throughout the state, including the second congressional district. This experience, and her contact list of district Democrats with whom she has worked, gives her a leg up in fund raising, gaining support, and experience to focus on what matters most in a campaign. She served as state senator in Senate District 49 before accepting a position as Fred Hubbell's running mate.
The Republican Party of Iowa will need new blood if they hope to be competitive in the district, rated a toss up by the Cook Political Report without Loebsack in the race. Three-time loser Mariannette Miller-Meeks (R-Ottumwa) went on to become a state senator in District 41. When contacted by Murphy, she said she would give the matter of running consideration. Murphy also contacted two-time loser Christopher Peters (D-Coralville) on vacation in Italy. Peters deferred comment until he returns to Iowa. In an open seat, Republicans would be foolish to run one of these two repeat candidates. The other non-Jim Leach opponent over the years? I met John Archer (R-Bettendorf) in Tipton in 2012 and felt creepy for a couple of days afterward. I doubt he's interested, and Jeff Kaufmann would likely stop him from running again if he were.
My state senator Zach Wahls gets mentioned a lot as a potential replacement for Loebsack. Few politicians have as bright a future ahead of them as Wahls appears to. I'm not privy to his plans, although I spend a little time with him at political events like I did with his predecessor, Bob Dvorsky. If one follows Wahls via legislative newsletter, on Medium, on Facebook and Twitter, it is clear he is learning the ropes of being a politician. He has political credibility, beating three opponents in the June 5, 2018 Democratic primary election with 63 percent of votes cast. Janice Weiner ran a serious primary campaign against Wahls, garnering 32 percent. Eric Dirth and Imad Youssif were on the ballot, but not competitive.
I know Tessler only by name and that because of watching her North Liberty operation of Yotopia, Iowa City's Original Froyo, open then shutter on Pacha Parkway as I drove by to retail jobs in Coralville over the last few years. The Iowa City location has been successful, having opened in 2011. The single time I stopped at the Clinton Street location, I had a frozen yogurt with Carsner. The snack was efficiently delivered and tasty.
Congressman Dave Loebsack chatting with constituents at Dodge Street Coffee, Iowa City on March 9, 2019.
I was an early adopter of Gmail with records going back to 2006. I searched for Veronica Tessler and came back with 23 distinct hits dating back to when she was a delegate to the 2008 Second District Convention. A google search shows plenty of activity, including support for an Iowa City gun violence protest where she was quoted in a March 31 Cedar Rapids Gazette article. If she announces for Congress, some of that may become relevant.
Other potential candidates have been mentioned in social media since Loebsack's announcement. Right now, I'm processing what Dave's departure from the Congress will mean personally and to the district. Loebsack did constituents a favor by timing retirement so there would be an open seat. I expect that if the four mentioned candidates jump into the race, more will follow.
Dave Loebsack has been a dependable part of my life since I first started our dialogue via email in 2005. Seems like I should be saying something besides Woody Guthrie's line, "So long it's been good to know ya," but that's what I have for now.
2 Responses to So Long Dave, It's Been Good to Know Ya!
Sorry, I can't 'like' this post. Not news I wanted to hear.